Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Future Cardiol. 2014 Nov;10(6):693-8. doi: 10.2217/fca.14.62.

Abstract

Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

Trial registration: ClinicalTrials.gov NCT00839228.

Keywords: cardiac spectroscopy; diastole; ejection fraction; heart failure; perhexiline.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Agents / therapeutic use*
  • Clinical Protocols
  • Double-Blind Method
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology*
  • Humans
  • Outcome Assessment, Health Care
  • Perhexiline / therapeutic use*
  • Stroke Volume / physiology*
  • Syndrome

Substances

  • Cardiovascular Agents
  • Perhexiline

Associated data

  • ClinicalTrials.gov/NCT00839228
  • EudraCT/2006-001109-28